Loading company…
Newark-based developer of T cell-based immunotherapies for cancer and chronic infectious diseases.
Founded in 2018 and headquartered in Newark, US, Virion Therapeutics, LLC develops T cell-based immunotherapies using genetically encoded checkpoint modifiers. Its lead product, VRON-0200, began its first-in-human study with enrollment starting in Q3 2023. CEO Andrew Luber leads the company, which took a USD 0.25 mn venture debt round on October 28, 2019, bringing its total raised to USD 4.05 mn.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in